Belzutifan
![]() | |
Clinical data | |
---|---|
Pronunciation | bell-ZOO-ti-fan |
Trade names | Welireg |
Other names | MK-6482, PT2977 |
License data |
|
Routes of administration | By mouth |
Drug class | Antineoplastic |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H12F3NO4S |
Molar mass | 383.34 g·mol−1 |
3D model (JSmol) | |
| |
|
Belzutifan, sold under the brand name Welireg, is a medication used for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma.[3][4][5][6][7][8] It is taken by mouth.[3]
The most common side effects include decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea.[4]
Belzutifan is an hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor.[3][4][9]
Belzutifan is the first drug to be awarded an "innovation passport" from the UK Medicines and Healthcare products Regulatory Agency (MHRA).[10][6] Belzutifan was approved for medical use in the United States in August 2021.[4][11] Belzutifan is the first hypoxia-inducible factor-2 alpha inhibitor therapy approved in the U.S.[11]
Medical uses
Belzutifan is indicated for treatment of adults with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.[4] Belzutifan was also found to be efficacious in an adolescent who had Pacak–Zhuang syndrome with polycythemia and paragangliomas.[12]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ https://pdf.hres.ca/dpd_pm/00066615.PDF [bare URL PDF]
- ^ a b c d "Welireg- belzutifan tablet, film coated". DailyMed. Retrieved 12 September 2021.
- ^ a b c d e f "FDA approves belzutifan for cancers associated with von Hippel-Lindau". U.S. Food and Drug Administration (FDA). 13 August 2021. Retrieved 13 August 2021.
This article incorporates text from this source, which is in the public domain.
- ^ "Belzutifan". SPS - Specialist Pharmacy Service. 18 March 2021. Retrieved 25 April 2021.
- ^ a b "MHRA awards first 'innovation passport' under new pathway". RAPS (Press release). Retrieved 25 April 2021.
- ^ "Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)" (Press release). Merck. 16 March 2016. Retrieved 25 April 2021 – via Business Wire.
- ^ "FDA Grants Priority Review to Belzutifan for von Hippel-Lindau Disease–Associated RCC". Cancer Network. Retrieved 26 April 2021.
- ^ Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. (April 2021). "Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis". Nat Med. 27 (5): 802–805. doi:10.1038/s41591-021-01324-7. PMC 9128828. PMID 33888901. S2CID 233371559.
- ^ "First Innovation Passport awarded to help support development and access to cutting-edge medicines". Medicines and Healthcare products Regulatory Agency (MHRA) (Press release). 26 February 2021. Retrieved 14 August 2021.
- ^ a b "FDA Approves Merck's Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor Welireg (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors" (Press release). Merck. 13 August 2021. Retrieved 13 August 2021 – via Business Wire.
- ^ Kamihara, Junne; Hamilton, Kayla V.; Pollard, Jessica A.; Clinton, Catherine M.; Madden, Jill A.; Lin, Jasmine; Imamovic, Alma; Wall, Catherine B.; Wassner, Ari J.; Weil, Brent R.; Heeney, Matthew M. (25 November 2021). "Belzutifan, a Potent HIF2α Inhibitor, in the Pacak–Zhuang Syndrome". New England Journal of Medicine. 385 (22): 2059–2065. doi:10.1056/NEJMoa2110051. ISSN 0028-4793. PMID 34818480. S2CID 244651726.
External links
- "Belzutifan". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT04195750 for "A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)" at ClinicalTrials.gov
- Clinical trial number NCT03401788 for "A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)" at ClinicalTrials.gov